Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Dr Seth Letterman tells Proactive that researchers at the scientific journal Genome Biology reported 99.7% co-linear identity between a U.S. smallpox vaccine developed in 1860 and horsepox virus.
Tonix’s TNX-801 is a horsepox-based live virus vaccine being developed as a potential vaccine to prevent smallpox and monkeypox. Dr Letterman says this means that essentially, this means the smallpox vaccine Tonix is developing has already been used in the US as a smallpox vaccine, which gives Tonix’s efforts a ‘predicate product.’
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…
In exchange for publishing services rendered by the Company on behalf of Tonix Pharmaceuticals named herein, including the promotion by the Company of Tonix Pharmaceuticals in any Content on the Site, the Company…
